Clinical Data Boehringer/Zealand dual-acting drug causes 16.6% weight loss PharmaphorumBoehringer/Zealand reveal first phase 3 data with dual GLP-1/glucagon weight-loss drug survodutide.Metabolic & GLP-1Read full story pharminent April 28, 2026 (Last updated: April 28, 2026) Pharmaphorum Boehringer/Zealand reveal first phase 3 data with dual GLP-1/glucagon weight-loss drug survodutide. Metabolic & GLP-1 Read full story Post navigation Previous: BioMarin acquires Amicus Therapeutics for $4.8bnNext: Seaport and Hemab target $180m IPOs as biotech listings accumulate Related Stories Clinical Data Novo Nordisk starts trialing lower maintenance doses of oral Wegovy pharminent August 21, 2026 Clinical Data Cancer vaccine win restores Wall Street’s faith in Moderna pharminent August 20, 2026 Clinical Data New Taiho, Cullian data heats up lung cancer drug battle pharminent August 13, 2026
